The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
Open accessAbstract
Highly pathogenic human respiratory coronaviruses cause acute lethal disease characterized by exuberant inflammatory responses and lung damage. However, the factors leading to lung pathology are not well understood. Using mice infected with SARS (Severe Acute Respiratory Syndrome)-CoV, we show that robust virus replication accompanied by delayed type I interferon (IFN-I) signaling orchestrates inflammatory responses and lung immunopathology with diminished survival. IFN-I remains detectable until after virus titers peak but early IFN-I administration ameliorates immunopathology. This delayed IFN-I signaling promotes the accumulation of pathogenic inflammatory monocyte-macrophages (IMMs), resulting in elevated lung cytokine/chemokine levels, vascular leakage and impaired virus-specific T cell responses. Genetic ablation of the IFN-αβ receptor (IFNAR) or IMM depletion protects mice from lethal infection, without affecting viral load. These results demonstrate that IFN-I and IMM promote lethal SARS-CoV infection and identify IFN-I and IMMs as potential therapeutic targets in patients infected with pathogenic coronavirus and perhaps other respiratory viruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Monocyte recruitment during infection and inflammation
Shi, C., & Pamer, E. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3070 · Cited by 3,015
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Multiple organ infection and the pathogenesis of SARS
Gu, J., Gong, E., Zhang, B., Zheng, J., Gao, Z., Zhong, Y., Zou, W., Zhan, J., Wang, S., Xie, Z., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050828 · Cited by 1,379
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
WONG, C. K., LAM, C. W. K., WU, A. K. L., IP, W. K., LEE, N. L. S., CHAN, I. H. S., LIT, L. C. W., HUI, D. S. C., CHAN, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,274
Middle East respiratory syndrome
Zumla, A., Hui, D. S., & Perlman, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,263
Self-citationTNF/iNOS-Producing Dendritic Cells Mediate Innate Immune Defense against Bacterial Infection
Serbina, N. V., Salazar-Mather, T. P., Biron, C. A., Kuziel, W. A., & Pamer, E. G. (2003) · Immunity · doi:10.1016/s1074-7613(03)00171-7 · Cited by 1,175
Severe acute respiratory syndrome
Peiris, J. S. M., Guan, Y., & Yuen, K. Y. (2004) · Nature Medicine · doi:10.1038/nm1143 · Cited by 1,139
Lung pathology of fatal severe acute respiratory syndrome
Nicholls, J. M., Poon, L. L., Lee, K. C., Ng, W. F., Lai, S. T., Leung, C. Y., Chu, C. M., Hui, P. K., Mak, K. L., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13413-7 · Cited by 1,076
Cited by
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Self-citationImbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,197
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Self-citationSingle-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
Self-citationPathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Molecular immune pathogenesis and diagnosis of COVID-19
Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.001 · Cited by 1,721
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.003 · Cited by 1,288
“[79] .”
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
Arunachalam, P. S., Wimmers, F., Mok, C. K. P., Perera, R. A. P. M., Scott, M., Hagan, T., Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., et al. (2020) · Science · doi:10.1126/science.abc6261 · Cited by 1,186
Pedersen, S. F., & Ho, Y.-C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137647 · Cited by 1,137
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., Guo, D., Hu, W., Yang, J., Tang, Z., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1747363 · Cited by 1,076
Phetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A., Burrell, L. M., Kent, S. J., Dore, G. J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01113-x · Cited by 1,015
Diverse functional autoantibodies in patients with COVID-19
Wang, E. Y., Mao, T., Klein, J., Dai, Y., Huck, J. D., Jaycox, J. R., Liu, F., Zhou, T., Israelow, B., Wong, P., et al. (2021) · Nature · doi:10.1038/s41586-021-03631-y · Cited by 992
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 983
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 938
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0778-2 · Cited by 901
Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection
Channappanavar, R., Fett, C., Mack, M., Ten Eyck, P. P., Meyerholz, D. K., & Perlman, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601896 · Cited by 871
Self-citationLiu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830
Self-citationLee, J. S., Park, S., Jeong, H. W., Ahn, J. Y., Choi, S. J., Lee, H., Choi, B., Nam, S. K., Sa, M., Kwon, J.-S., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd1554 · Cited by 825
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
Wen, W., Su, W., Tang, H., Le, W., Zhang, X., Zheng, Y., Liu, X., Xie, L., Li, J., Ye, J., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0168-9 · Cited by 730
Liu, B., Li, M., Zhou, Z., Guan, X., & Xiang, Y. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102452 · Cited by 763
The immunology and immunopathology of COVID-19
Merad, M., Blish, C. A., Sallusto, F., & Iwasaki, A. (2022) · Science · doi:10.1126/science.abm8108 · Cited by 751
Wang, J., Jiang, M., Chen, X., & Montaner, L. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covr0520-272r · Cited by 741
Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
Grant, R. A., Morales-Nebreda, L., Markov, N. S., Swaminathan, S., Querrey, M., Guzman, E. R., Abbott, D. A., Donnelly, H. K., Donayre, A., Goldberg, I. A., et al. (2021) · Nature · doi:10.1038/s41586-020-03148-w · Cited by 727
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655
Liu, J., Zheng, X., Tong, Q., Li, W., Wang, B., Sutter, K., Trilling, M., Lu, M., Dittmer, U., & Yang, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25709 · Cited by 620
COVID-19: Melatonin as a potential adjuvant treatment
Zhang, R., Wang, X., Ni, L., Di, X., Ma, B., Niu, S., Liu, C., & Reiter, R. J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117583 · Cited by 619
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway
Ghosh, S., Dellibovi-Ragheb, T. A., Kerviel, A., Pak, E., Qiu, Q., Fisher, M., Takvorian, P. M., Bleck, C., Hsu, V. W., Fehr, A. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.039 · Cited by 610
Self-citationThe signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Regulation of immune responses by the airway epithelial cell landscape
Hewitt, R. J., & Lloyd, C. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00477-9 · Cited by 591
The cGAS–STING pathway drives type I IFN immunopathology in COVID-19
Domizio, J. D., Gulen, M. F., Saidoune, F., Thacker, V. V., Yatim, A., Sharma, K., Nass, T., Guenova, E., Schaller, M., Conrad, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04421-w · Cited by 538
Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection
Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K., Vernardis, S. I., Egger, A.-S., Kreidl, M., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.05.012 · Cited by 561
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Self-citationCytokine storm induced by SARS-CoV-2
Song, P., Li, W., Xie, J., Hou, Y., & You, C. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.017 · Cited by 537
Galani, I.-E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E., Fragkou, P. C., Panou, V., Rapti, V., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00840-x · Cited by 503
Immunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516
SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling
Miorin, L., Kehrer, T., Sanchez-Aparicio, M. T., Zhang, K., Cohen, P., Patel, R. S., Cupic, A., Makio, T., Mei, M., Moreno, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016650117 · Cited by 527
The molecular virology of coronaviruses
Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J. M., & Glaunsinger, B. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.013930 · Cited by 525
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
Yuen, C.-K., Lam, J.-Y., Wong, W.-M., Mak, L.-F., Wang, X., Chu, H., Cai, J.-P., Jin, D.-Y., To, K. K.-W., Chan, J. F.-W., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1780953 · Cited by 524
Cytokine storm intervention in the early stages of COVID-19 pneumonia
Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J., Liao, H., Zhi, L., Wei, H., Zhang, Z., Qiu, Y., et al. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.04.002 · Cited by 513
“The use of IFN-αβ receptor inhibitors or antagonists could be considered as an approach to avoid excessive inflammatory reactions in late stage severe HCoV infection 27 .”
Severe Acute Respiratory Syndrome
Hui, D. S. C., & Zumla, A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.07.001 · Cited by 506
Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
Major, J., Crotta, S., Llorian, M., McCabe, T. M., Gad, H. H., Priestnall, S. L., Hartmann, R., & Wack, A. (2020) · Science · doi:10.1126/science.abc2061 · Cited by 503
COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice
Zheng, J., Wong, L.-Y. R., Li, K., Verma, A. K., Ortiz, M. E., Wohlford-Lenane, C., Leidinger, M. R., Knudson, C. M., Meyerholz, D. K., McCray, P. B., et al. (2021) · Nature · doi:10.1038/s41586-020-2943-z · Cited by 500
Self-citationType I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/xcdary · Cited by 466
COVID‐19: A Global Threat to the Nervous System
Koralnik, I. J., & Tyler, K. L. (2020) · Annals of Neurology · doi:10.1002/ana.25807 · Cited by 464
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
The hallmarks of COVID-19 disease
Tang, D., Comish, P., & Kang, R. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008536 · Cited by 447
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling
Israelow, B., Song, E., Mao, T., Lu, P., Meir, A., Liu, F., Alfajaro, M. M., Wei, J., Dong, H., Homer, R. J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201241 · Cited by 415
Is COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 434
Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors
Onomoto, K., Onoguchi, K., & Yoneyama, M. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00602-7 · Cited by 430
Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
Sardu, C., D’Onofrio, N., Balestrieri, M. L., Barbieri, M., Rizzo, M. R., Messina, V., Maggi, P., Coppola, N., Paolisso, G., & Marfella, R. (2020) · Diabetes Care · doi:10.2337/dc20-0723 · Cited by 424
Dysregulation of type I interferon responses in COVID-19
Acharya, D., Liu, G., & Gack, M. U. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0346-x · Cited by 454
Targeting the NLRP3 Inflammasome in Severe COVID-19
Freeman, T. L., & Swartz, T. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01518 · Cited by 405
Shi, C.-S., Nabar, N. R., Huang, N.-N., & Kehrl, J. H. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0181-7 · Cited by 404
Type III interferons disrupt the lung epithelial barrier upon viral recognition
Broggi, A., Ghosh, S., Sposito, B., Spreafico, R., Balzarini, F., Lo Cascio, A., Clementi, N., De Santis, M., Mancini, N., Granucci, F., et al. (2020) · Science · doi:10.1126/science.abc3545 · Cited by 402
Cai, Y., Zhou, H., Zhu, Y., Sun, Q., Ji, Y., Xue, A., Wang, Y., Chen, W., Yu, X., Wang, L., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0314-9 · Cited by 397
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Liu, W. J., Zhao, M., Liu, K., Xu, K., Wong, G., Tan, W., & Gao, G. F. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.006 · Cited by 395
Deng, X., Hackbart, M., Mettelman, R. C., O’Brien, A., Mielech, A. M., Yi, G., Kao, C. C., & Baker, S. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618310114 · Cited by 386
Henry, B. M., Vikse, J., Benoit, S., Favaloro, E. J., & Lippi, G. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.027 · Cited by 383
Zhang, D., Guo, R., Lei, L., Liu, H., Wang, Y., Wang, Y., Qian, H., Dai, T., Zhang, T., Lai, Y., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0720-470r · Cited by 383
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359
Chen, R., Sang, L., Jiang, M., Yang, Z., Jia, N., Fu, W., Xie, J., Guan, W., Liang, W., Ni, Z., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.003 · Cited by 380
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., Roshon, M., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd0110 · Cited by 357
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020) · Pulmonary Medicine · doi:10.1155/2020/6175964 · Cited by 352
Diabetes, infection risk and COVID-19
Erener, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101044 · Cited by 351
The type I interferon response in COVID-19: implications for treatment
Lee, J. S., & Shin, E.-C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00429-3 · Cited by 421
IL-6: Relevance for immunopathology of SARS-CoV-2
Gubernatorova, E. O., Gorshkova, E. A., Polinova, A. I., & Drutskaya, M. S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.009 · Cited by 343
MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19
Bilezikian, J. P., Bikle, D., Hewison, M., Lazaretti-Castro, M., Formenti, A. M., Gupta, A., Madhavan, M. V., Nair, N., Babalyan, V., Hutchings, N., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0665 · Cited by 343
An immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers, M. S., Delmonte, O. M., Ricotta, E. E., Fintzi, J., Fink, D. L., de Jesus, A. A. A., Zarember, K. A., Alehashemi, S., Oikonomou, V., Desai, J. V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144455 · Cited by 340
Liang, Y., Wang, M.-L., Chien, C.-S., Yarmishyn, A. A., Yang, Y.-P., Lai, W.-Y., Luo, Y.-H., Lin, Y.-T., Chen, Y.-J., Chang, P.-C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01022 · Cited by 339
Huang, J., Hume, A. J., Abo, K. M., Werder, R. B., Villacorta-Martin, C., Alysandratos, K.-D., Beermann, M. L., Simone-Roach, C., Lindstrom-Vautrin, J., Olejnik, J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.013 · Cited by 338
Bienvenu, L. A., Noonan, J., Wang, X., & Peter, K. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa284 · Cited by 338
Anka, A. U., Tahir, M. I., Abubakar, S. D., Alsabbagh, M., Zian, Z., Hamedifar, H., Sabzevari, A., & Azizi, G. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.12998 · Cited by 324
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Self-citationCollapsing Glomerulopathy in a Patient With COVID-19
Larsen, C. P., Bourne, T. D., Wilson, J. D., Saqqa, O., & Sharshir, M. A. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.04.002 · Cited by 314
Kirtipal, N., Bharadwaj, S., & Kang, S. G. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104502 · Cited by 306
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2
Guo, M., Tao, W., Flavell, R. A., & Zhu, S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00416-6 · Cited by 304
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures
Vanderheiden, A., Ralfs, P., Chirkova, T., Upadhyay, A. A., Zimmerman, M. G., Bedoya, S., Aoued, H., Tharp, G. M., Pellegrini, K. L., Manfredi, C., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00985-20 · Cited by 301
Type I and III interferon responses in SARS-CoV-2 infection
Kim, Y.-M., & Shin, E.-C. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00592-0 · Cited by 296
Hu, Y., Li, W., Gao, T., Cui, Y., Jin, Y., Li, P., Ma, Q., Liu, X., & Cao, C. (2017) · Journal of Virology · doi:10.1128/jvi.02143-16 · Cited by 294
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19
Lowery, S. A., Sariol, A., & Perlman, S. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.004 · Cited by 294
Self-citationA metabolic handbook for the COVID-19 pandemic
Ayres, J. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0237-2 · Cited by 292
Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response
Kindler, E., Thiel, V., & Weber, F. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.006 · Cited by 290
Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors
Hackbart, M., Deng, X., & Baker, S. C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921485117 · Cited by 289
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
Wang, N., Zhan, Y., Zhu, L., Hou, Z., Liu, F., Song, P., Qiu, F., Wang, X., Zou, X., Wan, D., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.005 · Cited by 287
Metadata
- Authors
- Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 19
- Issue
- 2
- Pages
- 181-193
- ISSN
- 1931-3128 (ISSN-L)
- OpenAlex
- W2267315119
- Cited by
- 1,419
- References
- 68
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.